Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA
复制标题
DOI：
10.1007/s00259-017-3728-y
复制
发表时间：
2017-08-01
影响因子：
9.1
通讯作者：
Fanti, Stefano
中科院分区：
文献类型：
--
作者：
Bozkurt, Murat Fani;Virgolini, Irene;Fanti, Stefano
目的与方法神经内分泌肿瘤是一类异质性肿瘤，核医学在诊断和靶向治疗中发挥着重要作用。本指南旨在帮助核医学医生推荐、执行、报告和解释使用Ga-68-DOTA结合多肽的生长抑素受体(SSTR)PET/CT显像和F-18-DOPA显像治疗各种神经内分泌肿瘤的结果。结果与结论EANM先前关于使用Ga-68结合多肽进行PET/CT肿瘤成像的操作指南已在杰出专家的帮助下根据该领域的相关最新文献进行了修订和更新。
Purpose & Methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using Ga-68-DOTA-conjugated peptides, as well as F-18-DOPA imaging for various neuroendocrine neoplasms. Results & Conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with Ga-68-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.